Epigral (EPIGRAL) Aandelenoverzicht
Epigral Limited produceert en verkoopt chlooralkali en aanverwante derivaten in India en internationaal. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 3/6 |
| Toekomstige groei | 4/6 |
| Prestaties in het verleden | 2/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 3/6 |
Beloningen
Risicoanalyse
EPIGRAL Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Epigral Limited Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | ₹1,202.70 |
| 52 Week Hoogtepunt | ₹1,850.00 |
| 52 Week Laag | ₹807.00 |
| Bèta | 0.19 |
| 1 maand verandering | 3.44% |
| 3 maanden verandering | -3.43% |
| 1 Jaar Verandering | -34.40% |
| 3 jaar verandering | 35.80% |
| 5 jaar verandering | 110.37% |
| Verandering sinds IPO | 195.90% |
Recent nieuws en updates
Nieuw narratief • Aug 04
Epoxy Expansion Risks And Capital Strain Will Shape A Tougher Yet Ultimately Constructive Outlook
Catalysts About Epigral Epigral is an integrated chemical producer with a portfolio spanning chlor alkali, epichlorohydrin, CPVC, chloromethanes, chlorotoluenes, hydrogen peroxide and planned epoxy resins and specialty intermediates. What are the underlying business or industry changes driving this perspective?
Narratiefupdate • Jul 21
EPIGRAL: New Subsidiary And Forthcoming Results Will Support Bullish View
Analysts have revised their fair value estimate for Epigral to ₹1,690 from ₹2,000, citing updated assumptions for revenue growth, profit margins, and future P/E expectations in their models. What's in the News for Epigral Epigral has incorporated a wholly owned subsidiary, Epigral Advanced Materials Limited, with the objective of manufacturing chemicals.
Nieuw narratief • Jul 21
Upcoming Specialty Expansion And Higher Chlorine Integration Will Strengthen Long Term Earnings Potential
Catalysts About Epigral Epigral is an Indian chemical producer with an integrated chlor alkali, derivatives and specialty chemicals portfolio. What are the underlying business or industry changes driving this perspective?Recent updates
Nieuw narratief • Aug 04
Epoxy Expansion Risks And Capital Strain Will Shape A Tougher Yet Ultimately Constructive Outlook
Catalysts About Epigral Epigral is an integrated chemical producer with a portfolio spanning chlor alkali, epichlorohydrin, CPVC, chloromethanes, chlorotoluenes, hydrogen peroxide and planned epoxy resins and specialty intermediates. What are the underlying business or industry changes driving this perspective?Narratiefupdate • Jul 21
EPIGRAL: New Subsidiary And Forthcoming Results Will Support Bullish View
Analysts have revised their fair value estimate for Epigral to ₹1,690 from ₹2,000, citing updated assumptions for revenue growth, profit margins, and future P/E expectations in their models. What's in the News for Epigral Epigral has incorporated a wholly owned subsidiary, Epigral Advanced Materials Limited, with the objective of manufacturing chemicals.Nieuw narratief • Jul 21
Upcoming Specialty Expansion And Higher Chlorine Integration Will Strengthen Long Term Earnings Potential
Catalysts About Epigral Epigral is an Indian chemical producer with an integrated chlor alkali, derivatives and specialty chemicals portfolio. What are the underlying business or industry changes driving this perspective?Narratiefupdate • Jun 07
EPIGRAL: Steady ₹2,000 View Will Reflect 2026 Board Meeting Outcomes
Analysts have kept Epigral's fair value estimate steady at ₹2,000. They point to broadly unchanged assumptions on discount rate, revenue growth, profit margin and future P/E as the basis for maintaining their price target view.Narratiefupdate • May 24
EPIGRAL: Steady ₹2,000 View Will Reflect 2026 Board Meeting Outcomes
Analysts are keeping the fair value estimate for Epigral steady at ₹2,000, citing slightly adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E as the key drivers behind the updated price target framework. What's in the News Board meeting scheduled for May 2, 2026, to review audited standalone and consolidated financial results for the fourth quarter and full year ended March 31, 2026, and to consider the statutory auditors' report (company filing).Analyse-artikel • May 08
Epigral Limited's (NSE:EPIGRAL) Sole Analyst Just Made A Substantial Upgrade To Their Forecasts
Celebrations may be in order for Epigral Limited ( NSE:EPIGRAL ) shareholders, with the covering analyst delivering a...Narratiefupdate • Apr 21
EPIGRAL: Steady ₹2,000 View Ahead Of 2026 Postal Ballot Outcome
Epigral's analyst fair value estimate is maintained at ₹2,000, with only marginal tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, as analysts fine tune their model inputs rather than changing their core view on the stock. What's in the News Epigral has scheduled a Special or Extraordinary Shareholders Meeting on May 19, 2026, to be conducted via postal ballot in India (Key Developments).Narratiefupdate • Apr 06
EPIGRAL: Steady ₹2,000 View Will Await Q3 Board Outcome
Analysts now keep Epigral's fair value estimate broadly unchanged at about ₹2,000 per share, with only minor tweaks to discount rate, revenue growth, profit margin and future P/E assumptions. This signals a largely steady view on the stock's valuation drivers.Narratiefupdate • Mar 23
EPIGRAL: Steady ₹2,000 Outlook Will Anticipate Q3 Board Meeting Outcome
Analysts have kept Epigral's fair value estimate steady at ₹2,000, with only minor tweaks to the discount rate, revenue growth, profit margin assumptions and future P/E supporting an unchanged price target. What's in the News A board meeting is scheduled on January 30, 2026 to consider the unaudited standalone and consolidated financial results for the third quarter and nine months ended December 31, 2025, along with the limited review report.Narratiefupdate • Mar 08
EPIGRAL: Steady ₹2,000 Fair Value Will Anticipate Q3 Board Review Outcome
Analysts have kept Epigral’s fair value estimate steady at ₹2,000, with only small tweaks to assumptions such as discount rate, revenue growth, profit margin and future P/E. This reflects fine tuning of their models rather than a material change in conviction.Narratiefupdate • Feb 21
EPIGRAL: Reaffirmed ₹2,000 Fair Value Will Support Future Repricing
Analysts have maintained Epigral's fair value estimate at ₹2,000. A slightly lower assumed future P/E and a marginally higher discount rate together support this unchanged price target.Narratiefupdate • Feb 07
EPIGRAL: New CFO And Reaffirmed Fair Value Will Support Future Repricing
Analysts now see fair value for Epigral at ₹2,000.00 per share, with the unchanged target based on updated assumptions on discount rate, revenue growth, profit margin and future P/E that together reflect a recalibration of their long term earnings and valuation framework. What's in the News A board meeting is scheduled on January 30, 2026 to consider unaudited standalone and consolidated financial results for the third quarter and nine months ended December 31, 2025, along with the limited review report from statutory auditors (company filing).Narratiefupdate • Jan 24
EPIGRAL: New CFO And Reaffirmed Fair Value Will Support Future Repricing
Analysts have maintained Epigral's fair value estimate at ₹2,000 after updating their assumptions for discount rate, revenue growth, profit margin and future P/E. These revisions support a recalibrated price target narrative rather than a change in the overall valuation direction.Narratiefupdate • Jan 09
EPIGRAL: New CFO Appointment Is Expected To Strengthen Future Financial Governance
Analysts have cut their price target on Epigral from ₹2,600 to ₹2,000, citing updated assumptions that combine slightly higher revenue growth and profit margins with a lower future P/E multiple. What's in the News Epigral appointed Mr. Rakesh Agrawal as Chief Financial Officer and Key Managerial Personnel, effective 10 November 2025, following a board decision based on the Nomination and Remuneration Committee's recommendation (Key Developments).Analyse-artikel • Dec 26
Returns On Capital At Epigral (NSE:EPIGRAL) Have Hit The Brakes
There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...Analyse-artikel • Nov 16
Downgrade: What You Need To Know About The Latest Epigral Limited (NSE:EPIGRAL) Forecasts
Market forces rained on the parade of Epigral Limited ( NSE:EPIGRAL ) shareholders today, when the covering analyst...Analyse-artikel • Nov 13
Epigral Limited Just Missed Earnings - But Analysts Have Updated Their Models
Epigral Limited ( NSE:EPIGRAL ) shareholders are probably feeling a little disappointed, since its shares fell 9.0% to...Analyse-artikel • Nov 11
If EPS Growth Is Important To You, Epigral (NSE:EPIGRAL) Presents An Opportunity
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analyse-artikel • Sep 28
Epigral (NSE:EPIGRAL) Has A Pretty Healthy Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Narratiefupdate • Aug 06
Capacity Expansion And Green Energy Will Unlock Global Opportunities
The increase in Epigral’s consensus analyst price target to ₹2600 primarily reflects higher anticipated future earnings multiples, as indicated by the rise in future P/E, while the discount rate remains stable. What's in the News Upcoming board meeting to consider un-audited Q1 FY26 results and review fund-raising proposals via debt instruments.Analyse-artikel • Aug 06
Epigral Limited Just Recorded A 98% EPS Beat: Here's What Analysts Are Forecasting Next
NSEI:EPIGRAL 1 Year Share Price vs Fair Value Explore Epigral's Fair Values from the Community and select yours As you...Analyse-artikel • Jul 30
Epigral Limited (NSE:EPIGRAL) Might Not Be As Mispriced As It Looks
With a price-to-earnings (or "P/E") ratio of 23.6x Epigral Limited ( NSE:EPIGRAL ) may be sending bullish signals at...Analyse-artikel • Jun 02
Investors Should Be Encouraged By Epigral's (NSE:EPIGRAL) Returns On Capital
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...Analyse-artikel • Apr 03
Subdued Growth No Barrier To Epigral Limited (NSE:EPIGRAL) With Shares Advancing 25%
Epigral Limited ( NSE:EPIGRAL ) shareholders would be excited to see that the share price has had a great month...Analyse-artikel • Feb 28
Calculating The Fair Value Of Epigral Limited (NSE:EPIGRAL)
Key Insights Epigral's estimated fair value is ₹1,644 based on 2 Stage Free Cash Flow to Equity With ₹1,630 share...
Nieuw narratief • Jan 16
Doubling CPVC And ECH Production Will Strengthen Future Prospects
Epigral is expanding production capacity and focusing on high-margin value-added products to enhance earnings and future growth.Analyse-artikel • Dec 18
Here's Why Epigral (NSE:EPIGRAL) Has Caught The Eye Of Investors
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analyse-artikel • Jul 04
Epigral Limited's (NSE:EPIGRAL) Shares Leap 29% Yet They're Still Not Telling The Full Story
Epigral Limited ( NSE:EPIGRAL ) shareholders would be excited to see that the share price has had a great month...Analyse-artikel • Apr 19
Epigral Limited (NSE:EPIGRAL) Looks Just Right With A 27% Price Jump
The Epigral Limited ( NSE:EPIGRAL ) share price has done very well over the last month, posting an excellent gain of...Analyse-artikel • Feb 23
Epigral Limited (NSE:EPIGRAL) Soars 28% But It's A Story Of Risk Vs Reward
Despite an already strong run, Epigral Limited ( NSE:EPIGRAL ) shares have been powering on, with a gain of 28% in the...Analyse-artikel • Feb 21
Epigral (NSE:EPIGRAL) Might Be Having Difficulty Using Its Capital Effectively
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Ideally, a business will...Analyse-artikel • Apr 05
Capital Investment Trends At Meghmani Finechem (NSE:MFL) Look Strong
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two...Rendement voor aandeelhouders
| EPIGRAL | IN Chemicals | IN Markt | |
|---|---|---|---|
| 7D | 9.6% | -1.4% | -0.2% |
| 1Y | -34.4% | -1.1% | 2.4% |
Rendement versus industrie: EPIGRAL presteerde slechter dan de Indian Chemicals -sector, die het afgelopen jaar een rendement van -1.1 % opleverde.
Rendement versus markt: EPIGRAL presteerde slechter dan Indian Market, dat het afgelopen jaar een rendement van 2.4 % opleverde.
Prijsvolatiliteit
| EPIGRAL volatility | |
|---|---|
| EPIGRAL Average Weekly Movement | 5.9% |
| Chemicals Industry Average Movement | 5.9% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 3.6% |
Stabiele aandelenkoers: EPIGRAL heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de Indian markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 6% ) van EPIGRAL is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2007 | 1,135 | Kaushal Soparkar | www.epigral.com |
Epigral Limited produceert en verkoopt chlooralkali en aanverwante derivaten in India en internationaal. Het bedrijf biedt gechloreerde polyvinylchlorideharsen (CPVC), epichloorhydrine, chloormethanen waardeketen, waterstofperoxide, natriumhydroxide, chloor, waterstof en kaliloogproducten aan. Het houdt zich ook bezig met de handel in agrochemische producten.
Epigral Limited Samenvatting
| EPIGRAL fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | ₹48.58b |
| Inkomsten(TTM) | ₹2.71b |
| Inkomsten(TTM) | ₹26.26b |
19.1x
Koers/Winstverhouding2.0x
P/S-verhoudingIs EPIGRAL overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| EPIGRAL resultatenrekening (TTM) | |
|---|---|
| Inkomsten | ₹26.26b |
| Kosten van inkomsten | ₹16.48b |
| Brutowinst | ₹9.78b |
| Overige uitgaven | ₹7.07b |
| Inkomsten | ₹2.71b |
Laatst gerapporteerde inkomsten
Jun 30, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 62.82 |
| Brutomarge | 37.24% |
| Nettowinstmarge | 10.32% |
| Schuld/Eigen Vermogen Verhouding | 25.8% |
Hoe presteerde EPIGRAL op de lange termijn?
Bekijk historische prestaties en vergelijkingDividenden
0.4%
Huidig dividendrendement6%
UitbetalingsratioBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/08/24 11:16 |
| Aandelenkoers aan het einde van de dag | 2026/08/24 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2026/03/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Epigral Limited wordt gevolgd door 4 analisten. 2 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| null null | BP Wealth Management Private Limited |
| null null | Emkay Global Financial Services Ltd. |
| Meet Vora | Emkay Global Financial Services Ltd. |